Taltz and Zepbound Combination Therapy Demonstrates Superior Efficacy in Psoriatic Arthritis Treatment

GasGuzzler · 2026-01-12T17:14:22+00:00

Eli Lilly's Phase 3b trial showed that the combination of Taltz and Zepbound significantly improves outcomes in psoriatic arthritis patients with weight issues, achieving a 31.7% response rate compared to 0.8% with Taltz alone. The study highlights a potential new treatment strategy.

GasGuzzler

2026-01-12 17:14:22

Abstract generation in progress

Eli Lilly (LLY) has revealed encouraging findings from the TOGETHER-PsA open-label Phase 3b clinical trial, which evaluated the simultaneous administration of Taltz and Zepbound in adults suffering from both active psoriatic arthritis and weight-related conditions. The trial data showcased a significant advantage of combination therapy over single-agent treatment approaches.

According to the 36-week trial data, patients receiving the Taltz and Zepbound combination achieved impressive dual outcomes. The cohort using both medications demonstrated a 31.7% response rate—defined as achieving at least 50% improvement in psoriatic arthritis disease activity markers while simultaneously attaining a minimum 10% weight reduction. This performance starkly contrasted with the 0.8% response rate observed in patients treated with Taltz monotherapy alone.

The dual-endpoint achievement addresses a critical clinical need, as obesity and overweight conditions frequently complicate psoriatic arthritis management. The combination approach effectively tackled both disease components simultaneously, which represents a notable advancement in treatment paradigms for this patient population. Beyond the primary objective, the study also successfully achieved all designated key secondary endpoints, further substantiating the therapeutic benefit of the combined regimen.

Eli Lilly plans to present comprehensive 36-week efficacy and safety data from this trial at upcoming medical conferences. These detailed results will inform subsequent regulatory discussions regarding potential approval pathways. Additionally, the company continues advancing the TOGETHER-PsO trial, which explores similar combination therapy in psoriasis patients, with topline results anticipated to emerge during the first half of 2026.

The positive trial readout underscores the therapeutic potential of targeting multiple disease pathways concurrently and may reshape treatment strategies for inflammatory arthritis patients with concurrent metabolic conditions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.